Plexxikon, a member of the Daiichi Sankyo Group since 2011, works in the structureguided discovery and development of novel small-molecule pharmaceuticals to treat human disease. The company’s lead drug Zelboraf (vemurafenib/PLX4032) was approved by the FDA in August 2011 and is copromoted in the United States by Daiichi Sankyo, Inc. [ Read More ]
K. Peter Hirth, PhD
Dr Hirth cofounded Plexxikon in December 2000 and has more than 25 years of biotechnology and pharmaceutical discovery and development experience. Previously, he was president of Sugen, Inc., where he helped advance several kinase inhibitors through clinical trials. Dr Hirth received his PhD in molecular genetics from Heidelberg University and completed his postdoctoral work at the University of California, San Diego.